Presentation is loading. Please wait.

Presentation is loading. Please wait.

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,

Published byDebra Joseph Modified over 5 years ago

Similar presentations

Presentation on theme: "IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,"— Presentation transcript:

1 IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis 
James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas, PhD, Patrick A. Haslett, MB, BS, Krista M. Phipps, Gregory S. Cameron, PhD, Juliet McColm, MD, Artemis Katcherian, Inna Cueto, Traci White, Subhashis Banerjee, MD, Robert W. Hoffman, DO  Journal of Allergy and Clinical Immunology  Volume 130, Issue 1, Pages e9 (July 2012) DOI: /j.jaci Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 IL-17 neutralization results in decreased keratinocyte proliferation and differentiation, leukocyte infiltration, and keratinocyte release of inflammatory cytokines. A representative example of serial skin biopsy specimens from a subject treated with 150 mg of ixekizumab is presented. Histologic analysis included hematoxylin and eosin (H&E) staining. Immunohistochemical analysis included staining for keratin 16 (K16), Ki67, CD3, CD11c, LL37/cathelicidin, S100A7, S100A8, β-defensin 2 (BD2), and DC-LAMP. Scale bar = 50 μm. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 IL-17 neutralization results in decreased expression of cytokines from multiple T-cell subsets. At baseline and weeks 2 and 6, mRNA expression for keratin 16 (K16) and lipocalin (LCN), an IL-17 target gene, were analyzed, as were mRNA expression levels for the T-cell cytokines IFN-γ, IL-17A/F, and IL-22 and the dendritic cell cytokine IL-23. *P < .05 versus baseline. Data are shown as means ± SEMs. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Identification of genes modulated greater than 6-fold by IL-17 neutralization. A, DEGs that had a greater than 6-fold change compared with baseline values in the 150-mg group were identified and clustered. mRNA expression of these genes is presented for the placebo group for comparison. B, Gene expression data for untreated lesional skin biopsy specimens (LS) and nonlesional skin biopsy specimens (NS) from a previous experiment.28 The genes are ordered according to the clustering results in Fig 3, A. Asterisks represent those genes that are synergistically regulated by TNF-α and IL-17. Plus signs indicate those that are additively coregulated by TNF-α and IL-17. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Comparison of treatment effect at week 2 for ixekizumab, etanercept, and placebo. A and B, Mean (95% CI) for fold change from baseline for each treatment for RT-PCR (Fig 4, A) and histologic variables (Fig 4, B). C, Venn diagram summarizing the number of genes among those in the psoriasis transcriptome with improvement of at least 75%. D, Estimated density distribution of the treatment effect multiplied by the sign of the lesional (LS) versus nonlesional (NL) direction to show only the magnitude of the change toward resolution. The insert graph shows the density distribution of the difference in effect between ixekizumab and etanercept for all genes and the genes in the psoriasis transcriptome. For all genes, one can see a 0-centered distribution (equal effects), but for the psoriasis genes, there is a shift to the right, indicating larger changes with ixekizumab treatment among psoriasis genes. E, Proportion of psoriasis genes improved by more than 75% in each gene set. F, Average improvement in each gene set. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E1 Analysis for batch effect between the clinical studies of LY and etanercept. A and B, Principal component analysis showing the first 2 components of expression values before (Fig E1, A) and after (Fig E1, B) adjustment for a batch effect. C and D, Principal component analysis of the treatment effect for each subject (after treatment vs baseline lesion) on the original data (Fig E1, C) and after adjustment (Fig E1, D). E, Density distribution function for the treatment effect at week 2 for both treatments before and after adjustment. F, Density distribution function for the differences in treatment effect at week 2 before and after adjustment. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

7 Fig E2 Representative example from a subject treated with placebo: keratinocyte proliferation and differentiation, leukocyte infiltration, and keratinocyte release of inflammatory cytokines. A representative example from a subject treated with placebo is presented. Histologic analysis included hematoxylin and eosin (H&E) staining. Immunohistochemical analysis included staining for keratin 16 (K16), Ki76, CD3, CD11c, LL37/cathelicidin, S100A7, S100A8, β-defensin 2 (BD2), and DC-LAMP. Scale bar = 50 μm. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

8 Fig E3 IL-17 neutralization results in decreased hyperplasia and leukocyte infiltration. Histologic analysis included hematoxylin and eosin staining. Immunohistochemical analysis included staining for keratin 16 (K16), Ki76, CD3, CD11c, LL37/cathelicidin, S100A7, S100A8, β-defensin 2 (BD2), and DC-LAMP. Cell counts are shown per square millimeter. *P < .05 versus baseline value. Data are shown as means ± SEMs. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

9 Fig E4 IL-17 neutralization effects on some IL-17 target genes and on TNF-α and IL-12. mRNA expression for keratin 16 (K16) and lipocalin (LCN) is shown. IL-17 target gene were analyzed, as were mRNA expression levels for the T-cell cytokines IFN-γ, IL-17A/F, and IL-22 and the dendritic cell cytokine IL-23. *P < .05 versus baseline. Data are shown as means ± SEMs. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

10 Fig E5 Correlation between week 2 response to treatment for Ki67 and IL-19. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

11 Fig E6 Correlation between μ scores of epidermal response with measures of infiltrating leukocytes, associated cytokines, and defined cytokine response genes in keratinocytes. Each graph is a scatter plot of μ scores versus expression of β-defensin 4 (DEFB4), lipocalin (LCN), IL-8, CXCL1, MX1, CXCL9, CXCL10, IL-17A, IL-17F, IFN-γ, IL-22, the p19 subunit of IL-12, the p40 subunit of IL-12/23, and the p35 subunit of IL-23 and cell counts of CD3+ T cells and CD11c+ dendritic cells in the epidermis and total CD11c+ dendritic cells. Journal of Allergy and Clinical Immunology  , e9DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis  James G. Krueger, MD, Scott Fretzin, MD, Mayte Suárez-Fariñas,"

Similar presentations

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy  Erik Wambre, PhD, Jonathan.
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,
Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,

Anti–IL-23A mAb BI for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose,
Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer  Tali Czarnowicki, MD, Dana Malajian, BA, Saakshi Khattri, MD,

Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer  Tali Czarnowicki, MD, Dana Malajian, BA, Saakshi Khattri, MD,
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology  Saakshi Khattri, MD, Avner.

Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology  Saakshi Khattri, MD, Avner.
Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence  Mariya Rozenblit, BA, Mayte Suarez-Farinas,

Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence  Mariya Rozenblit, BA, Mayte Suarez-Farinas,
Jason E. Hawkes, MD, Tom C. Chan, MD, PhD, James G. Krueger, MD, PhD 

Jason E. Hawkes, MD, Tom C. Chan, MD, PhD, James G. Krueger, MD, PhD 
Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 
Mechanisms of IFN-γ–induced apoptosis of human skin keratinocytes in patients with atopic dermatitis  Ana Rebane, PhD, Maya Zimmermann, PhD, Alar Aab,

Mechanisms of IFN-γ–induced apoptosis of human skin keratinocytes in patients with atopic dermatitis  Ana Rebane, PhD, Maya Zimmermann, PhD, Alar Aab,
RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications  Mayte.

RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications  Mayte.
An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,

An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis  Amy S. Paller, MD, MS, Yael Renert-Yuval, MD, Maria Suprun, MPH,
Epigenetic regulation of established human type 1 versus type 2 cytokine responses  Ruey-Chyi Su, PhD, Allan B. Becker, MD, Anita L. Kozyrskyj, PhD, Kent.

Epigenetic regulation of established human type 1 versus type 2 cytokine responses  Ruey-Chyi Su, PhD, Allan B. Becker, MD, Anita L. Kozyrskyj, PhD, Kent.
Reduced IFN-γ receptor expression and attenuated IFN-γ response by dendritic cells in patients with atopic dermatitis  Eva Gros, MSc, Susanne Petzold,

Reduced IFN-γ receptor expression and attenuated IFN-γ response by dendritic cells in patients with atopic dermatitis  Eva Gros, MSc, Susanne Petzold,
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis  Mayte Suárez-Fariñas, PhD,

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis  Mayte Suárez-Fariñas, PhD,
MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers  Thomas X. Lu,
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome 

Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome 
Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment  Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.

Inflammatory marker analysis in psoriatic skin under topical phosphodiesterase 4 inhibitor treatment  Lennart M. Roesner, PhD, Petra Kienlin, Gabriele.
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,

Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis  Jennifer D. Hamilton, PhD, Mayte Suárez-Fariñas,
Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis  Julia K. Gittler, BA,

Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis  Julia K. Gittler, BA,
Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 

Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion 

Similar presentations

Ads by Google